Agaplesion Diakonieklinikum Rotenburg gGmbH
- Address
- lock Available on a paid plan
Neoplasms
At Agaplesion Diakonieklinikum Rotenburg gGmbH, clinical research in oncology focuses on cancers such as locally advanced, unresectable, or metastatic non-small cell lung cancer and follicular lymphoma. The trials are designed to compare new treatment approaches with standard care and to improve how effectively these cancers are controlled.
- Testing new cancer therapies for better disease control
- Evaluating treatment effectiveness in lung cancer and lymphoma
- Studying options for previously untreated patients with advanced malignancies
These studies reflect a strong interest in advancing tumor treatment through more effective and targeted care.
Hemic and Lymphatic Diseases
Research in hematology at the site includes studies of chronic lymphocytic leukemia and follicular lymphoma, with a particular focus on patients at higher risk of disease progression. The goal is to assess whether newer combination treatments can extend the time before the disease worsens.
- Exploring improved therapy for high-risk CLL
- Comparing treatment strategies in follicular lymphoma
- Supporting better outcomes for patients with blood cancers
This work centers on finding more effective ways to manage hematologic malignancies and reduce the burden of relapse.
Nervous System Diseases
The ACH Darmkrebszentrum also contributes to research on chemotherapy-induced polyneuropathy, a nerve-related complication that can affect patients undergoing cancer treatment. The trial aims to reduce symptoms and help preserve quality of life during therapy.
- Preventing or reducing nerve damage linked to cancer treatment
- Improving comfort and daily functioning in patients receiving chemotherapy
- Assessing supportive care approaches for polyneuropathy
By addressing this side effect, the site is helping to improve the overall experience of oncology care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Agaplesion Diakonieklinikum Rotenburg gGmbH
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS | Institut fuer Frauengesundheit GmbH | Phase III | Recruiting | Oct 2022 | — |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obinutuzumab | 2 | Unknown | 2022-04-22 | 2024-06-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.